ATE205854T1 - Peptide als amylin-agonisten und ihre verwendung - Google Patents

Peptide als amylin-agonisten und ihre verwendung

Info

Publication number: ATE205854T1
Authority: AT; Austria
Prior art keywords: pro; ser; thr; asn; leu
Prior art date: 1991-11-19

Application number

AT92924442T

Other languages

English (en)

Inventor

Laura S L Gaeta

Howard Jones

Elisabeth Albrecht

Original Assignee

Amylin Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-11-19

Filing date

1992-11-19

Publication date

2001-10-15

1992-11-19 Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc

2001-10-15 Application granted granted Critical

2001-10-15 Publication of ATE205854T1 publication Critical patent/ATE205854T1/de

Links

102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
229940127438 Amylin Agonists Drugs 0.000 title 1
102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 1
108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000003282 alkyl amino group Chemical group 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
125000001691 aryl alkyl amino group Chemical group 0.000 abstract 1
125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
125000001769 aryl amino group Chemical group 0.000 abstract 1
125000004104 aryloxy group Chemical group 0.000 abstract 1
125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
125000004663 dialkyl amino group Chemical group 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
238000010532 solid phase synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT92924442T 1991-11-19 1992-11-19 Peptide als amylin-agonisten und ihre verwendung ATE205854T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US79426691A	1991-11-19	1991-11-19
PCT/US1992/009842 WO1993010146A1 (en)	1991-11-19	1992-11-19	Amylin agonist peptides and uses therefor

Publications (1)

Publication Number	Publication Date
ATE205854T1 true ATE205854T1 (de)	2001-10-15

Family

ID=25162163

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92924442T ATE205854T1 (de)	1991-11-19	1992-11-19	Peptide als amylin-agonisten und ihre verwendung

Country Status (17)

Country	Link
EP (2)	EP0567626B1 (de)
JP (4)	JP2902115B2 (de)
AT (1)	ATE205854T1 (de)
AU (1)	AU714439B2 (de)
CA (1)	CA2100745C (de)
CZ (1)	CZ288029B6 (de)
DE (1)	DE69232064T2 (de)
DK (1)	DK0567626T3 (de)
ES (1)	ES2161697T3 (de)
FI (1)	FI118601B (de)
GR (1)	GR3036794T3 (de)
HK (1)	HK1041891A1 (de)
MD (1)	MD960317A (de)
NO (2)	NO324405B1 (de)
RU (1)	RU2130463C1 (de)
SK (1)	SK88793A3 (de)
WO (1)	WO1993010146A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU222249B1 (hu)	1991-03-08	2003-05-28	Amylin Pharmaceuticals Inc.	Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5625032A (en) *	1993-07-21	1997-04-29	Amylin Pharmaceuticals, Inc.	Selective amylin antagonist peptides and uses therefor
CZ69596A3 (en)	1993-09-07	1997-06-11	Amylin Pharmaceuticals Inc	Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US6143718A (en) *	1995-06-07	2000-11-07	Amylin Pharmaceuticals, Inc.	Treatment of Type II diabetes mellutis with amylin agonists
US5739106A (en) *	1995-06-07	1998-04-14	Rink; Timothy J.	Appetite regulating compositions
US7312196B2 (en)	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US6410511B2 (en)	1997-01-08	2002-06-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US7101853B2 (en) *	1997-05-06	2006-09-05	Amylin Pharmaceuticals, Inc.	Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en)	1997-06-06	2011-03-22	Amylin Pharmaceuticals, Inc.	Methods for treating obesity
EP1044015B1 (de) *	1998-01-09	2008-10-08	Amylin Pharmaceuticals, Inc.	Formulierungen für amylin peptidagonisten mit insulin
ATE366259T1 (de) *	1999-03-04	2007-07-15	Praecis Pharm Inc	Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren
GB0002952D0 (en) *	2000-02-09	2000-03-29	Pharma Mar Sa	Process for producing kahalalide F compounds
RU2228174C2 (ru) *	2000-04-10	2004-05-10	Помыткин Игорь Анатольевич	Янтарнокислый бис(2-гидрокси-n,n,n-триметилэтанаминий) для лечения инсулиновой резистентности, сахарного диабета, гиперлипидемии и дислипидемии
GB0128583D0 (en)	2001-11-28	2002-01-23	Rsr Ltd	Detection of autoantibodies indicative of diabetes
WO2004037168A2 (en)	2002-10-18	2004-05-06	Amylin Pharmaceuticals, Inc.	Treatment of pancreatitis with amylin
GB0304367D0 (en) *	2003-02-26	2003-04-02	Pharma Mar Sau	Methods for treating psoriasis
JP2007527365A (ja) *	2003-03-18	2007-09-27	アプライドリサーチシステムズエーアールエスホールディングナームロゼフェンノートシャップ	アミリン凝集阻害剤およびその使用
TW200637872A (en) *	2004-10-26	2006-11-01	Lonza Ag	Thiol group protection and cyclization in solid-phase peptide synthesis
US8394765B2 (en)	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
CN101094689B (zh)	2004-11-01	2013-06-12	安米林药品有限责任公司	治疗肥胖以及肥胖相关疾病和病症的方法
CN102343084A (zh)	2005-03-31	2012-02-08	安米林药品公司	用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
WO2008028914A1 (en)	2006-09-07	2008-03-13	Nycomed Gmbh	Combination treatment for diabetes mellitus
US8309522B2 (en)	2007-02-05	2012-11-13	Amylin Pharmaceuticals, Llc	Neuromedin and FN-38 peptides for treating psychiatric diseases
JP2009149684A (ja) *	2009-03-11	2009-07-09	Amylin Pharmaceut Inc	アミリン作動薬ペプチド用製剤
CA2755068C (en)	2009-03-12	2018-11-06	Keybioscience Ag	Treatment of diabetes and metabolic syndrome
AR097701A1 (es) *	2013-09-19	2016-04-13	Zealand Pharma As	Análogos de amilina
MX2016005995A (es)	2013-11-05	2016-08-17	Ben-Gurion Univ Of The Negev Res And Dev Authority	Compuestos para el tratamiento de diabetes y complicaciones de la enfermedad derivadas de la misma.
CA2947587C (en) *	2014-05-02	2022-10-18	The Research Foundation For The State University Of New York	Islet amyloid polypeptides with improved solubility
BR112017019378A2 (pt) *	2015-03-18	2019-02-19	Zealand Pharma A/S	análogos de amilina
US10071140B2 (en)	2016-09-09	2018-09-11	Zealand Pharma A/S	Amylin analogues
WO2018144671A1 (en)	2017-02-01	2018-08-09	The Research Foundation For The State University Of New York	Mutant islet amyloid polypeptides with improved solubility and methods for using the same
KR102130354B1 (ko) *	2019-08-14	2020-07-06	엘아이지넥스원 주식회사	코어 제거용 이형장치
TWI880227B (zh)	2022-05-30	2025-04-11	丹麥商西蘭製藥公司	澱粉素類似物之液體調配物
IL319599A (en)	2022-09-19	2025-05-01	Zealand Pharma As	Combination therapy
MX2025015167A (es)	2023-06-21	2026-02-03	Zealand Pharma As	Analogos con propiedades mejoradas
TW202504913A (zh)	2023-06-21	2025-02-01	丹麥商西蘭製藥公司	減重
TW202517291A (zh)	2023-06-30	2025-05-01	丹麥商西蘭製藥公司	組合療法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5120712A (en) *	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
GB8720115D0 (en) *	1987-08-26	1987-09-30	Cooper G J S	Treatment of diabetes mellitus
AU631112B2 (en) *	1988-01-11	1992-11-19	Amylin Corporation	Treatment of type 2 diabetes mellitus
ES2080802T3 (es) *	1989-07-10	1996-02-16	Amylin Pharmaceuticals Inc	Uso de un antagonista de amilina en la preparacion de un medicamento para el tratamiento de la obesidad e hipertension intrinseca y desordenes asociados.
US5234906A (en) *	1991-01-10	1993-08-10	Amylin Pharmaceuticals, Inc.	Hyperglycemic compositions
WO1992015317A1 (en) *	1991-03-08	1992-09-17	Amylin Pharmaceuticals, Inc.	Synthetic preparation of amylin and amylin analogues

1992
- 1992-11-19 CA CA002100745A patent/CA2100745C/en not_active Expired - Lifetime
- 1992-11-19 MD MD96-0317A patent/MD960317A/ro unknown
- 1992-11-19 ES ES92924442T patent/ES2161697T3/es not_active Expired - Lifetime
- 1992-11-19 EP EP92924442A patent/EP0567626B1/de not_active Expired - Lifetime
- 1992-11-19 JP JP5509441A patent/JP2902115B2/ja not_active Expired - Lifetime
- 1992-11-19 SK SK887-93A patent/SK88793A3/sk unknown
- 1992-11-19 DE DE69232064T patent/DE69232064T2/de not_active Expired - Lifetime
- 1992-11-19 RU RU93053497A patent/RU2130463C1/ru active
- 1992-11-19 CZ CZ19931689A patent/CZ288029B6/cs not_active IP Right Cessation
- 1992-11-19 AT AT92924442T patent/ATE205854T1/de active
- 1992-11-19 EP EP01114132A patent/EP1162207A1/de not_active Ceased
- 1992-11-19 WO PCT/US1992/009842 patent/WO1993010146A1/en not_active Ceased
- 1992-11-19 DK DK92924442T patent/DK0567626T3/da active
1993
- 1993-07-16 FI FI933252A patent/FI118601B/fi not_active IP Right Cessation
- 1993-07-19 NO NO19932603A patent/NO324405B1/no not_active IP Right Cessation
1997
- 1997-01-31 AU AU12456/97A patent/AU714439B2/en not_active Expired
1998
- 1998-09-30 JP JP10277573A patent/JPH11152299A/ja not_active Withdrawn
2001
- 2001-10-04 GR GR20010401656T patent/GR3036794T3/el unknown
2002
- 2002-05-02 HK HK02103291.8A patent/HK1041891A1/en unknown
2003
- 2003-01-15 JP JP2003007228A patent/JP2003238594A/ja not_active Withdrawn
2006
- 2006-02-03 JP JP2006027334A patent/JP4018116B2/ja not_active Expired - Lifetime
2007
- 2007-06-25 NO NO20073265A patent/NO20073265L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU1245697A (en)	1997-03-27
MD960317A (ro)	1998-05-31
WO1993010146A1 (en)	1993-05-27
NO932603D0 (no)	1993-07-19
DE69232064T2 (de)	2002-03-28
CA2100745C (en)	2007-07-31
AU3075392A (en)	1993-06-15
NO324405B1 (no)	2007-10-08
EP0567626A1 (de)	1993-11-03
AU714439B2 (en)	2000-01-06
HK1041891A1 (en)	2002-07-26
JPH06504794A (ja)	1994-06-02
GR3036794T3 (en)	2002-01-31
CA2100745A1 (en)	1993-05-20
CZ288029B6 (cs)	2001-04-11
NO20073265L (no)	1993-09-17
FI933252A0 (fi)	1993-07-16
JP2006213716A (ja)	2006-08-17
EP1162207A1 (de)	2001-12-12
RU2130463C1 (ru)	1999-05-20
JP4018116B2 (ja)	2007-12-05
AU673147B2 (en)	1996-10-31
EP0567626B1 (de)	2001-09-19
JPH11152299A (ja)	1999-06-08
FI933252L (fi)	1993-08-23
JP2902115B2 (ja)	1999-06-07
DE69232064D1 (de)	2001-10-25
DK0567626T3 (da)	2001-12-17
ES2161697T3 (es)	2001-12-16
NO932603L (no)	1993-09-17
FI118601B (fi)	2008-01-15
JP2003238594A (ja)	2003-08-27
CZ168993A3 (en)	1994-04-13
SK88793A3 (en)	1994-12-07

Legal Events

Date	Code	Title	Description
2002-01-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
ATE205854T1 (de)	2001-10-15	Peptide als amylin-agonisten und ihre verwendung
DE10075019I1 (de)	2000-09-21	Neue Proteine mit TNF-Hemmender wirkung und ihre Herstellung.
DE3750197D1 (de)	1994-08-18	Antagonisten des Fibroblasten-Wachstumsfaktors.
IL89541A0 (en)	1989-09-10	Urethane-protected amino acid-n-carboxyanhydrides and their use in the synthesis of polypeptides
WO1995030750A8 (fr)	1999-07-29	Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
ATE81779T1 (de)	1992-11-15	Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
CA2094027A1 (en)	1992-04-19	Osteogenic peptides
RU94036776A (ru)	1996-09-27	Домен ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена ингибитора протеазы
ES2054365T3 (es)	1994-08-01	Inhibicion de la via de la regla del n final en celulas vivas.
JPS55143945A (en)	1980-11-10	Novel polypeptide
BR9306272A (pt)	1998-06-23	Peptídeo e composiçao farmacêutica
ZA896980B (en)	1990-06-27	Peptide compounds
Huang et al.	1992	An antiplatelet peptide, gabonin, from Bitis gabonica snake venom
EP0292257A3 (de)	1990-06-06	Peptide mit ANF-Wirksamkeit
ATE124955T1 (de)	1995-07-15	Substrat-peptide.
ES2044928T3 (es)	1994-01-16	Enzima alfa-amidante en terminal c y procedimiento para la produccion y el uso del mismo.
EP0232435A3 (de)	1988-02-24	Serumthymischer Faktor von Peptidanalogen und deren Verfahren zur Herstellung
EP0687685A4 (de)	1998-07-01	Physiologisch-aktive peptide
CA2083286A1 (en)	1992-01-27	Recombinant fibrinogenases, preparation and use thereof
ATE123056T1 (de)	1995-06-15	Ancrod-proteine, ihre herstellung und verwendung.
DK200200302A (da)	2002-02-27	Rekombinante polypeptider omfattende aminosyresekvensen af moden vævsfaktorinhibitor (TFI), polypeptidfragmenter deraf, ekspressionsvektorer der koder for disse, værtsceller transformeret dermed, og fremgangsmåde til fremstilling af et ........
ES2051152B1 (es)	1994-12-16	Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.
Judd et al.	1990	Peptides: chemistry, biology, and pharmacology
ES2069476A1 (es)	1995-05-01	Procedimiento de sintesis de peptidos con capacidad de detectar anticuerpos ant-virus de la hepatitis c (vhc) en suero de individuos afectados.